Cargando…

Immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in aged people

The immune factors associated with impaired SARS-CoV-2 vaccine response in elderly people are mostly unknown. We studied individuals older than 60 and younger than 60 years, who had been vaccinated with SARS-CoV-2 BNT162b2 mRNA, before and after the first and second dose. Aging was associated with a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vitallé, Joana, Pérez-Gómez, Alberto, Ostos, Francisco José, Gasca-Capote, Carmen, Jiménez-León, María Reyes, Bachiller, Sara, Rivas-Jeremías, Inmaculada, Silva-Sánchez, Maria del Mar, Ruiz-Mateos, Anabel M., Martín-Sánchez, María Ángeles, López-Cortes, Luis Fernando, Rafii-El-Idrissi Benhnia, Mohammed, Ruiz-Mateos, Ezequiel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536264/ https://www.ncbi.nlm.nih.gov/pubmed/35943812 http://dx.doi.org/10.1172/jci.insight.161045

Ejemplares similares

Deciphering the quality of SARS‐CoV‐2 specific T‐cell response associated with disease severity, immune memory and heterologous response
por: Pérez‐Gómez, Alberto, et al.
Publicado: (2022)

Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection
por: Pérez-Gómez, Alberto, et al.
Publicado: (2021)

Biocompatible and Thermoresistant Hydrogels Based on Collagen and Chitosan
por: Sánchez-Cid, Pablo, et al.
Publicado: (2022)

Type-A Gelatin-Based Hydrogel Infiltration and Degradation in Titanium Foams as a Potential Method for Localised Drug Delivery
por: Mehdi-Sefiani, Hanaa, et al.
Publicado: (2023)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

A metagenome-wide association study of HIV disease progression in HIV controllers
por: Real, Luis Miguel, et al.
Publicado: (2023)

Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients
por: Broseta, José Jesús, et al.
Publicado: (2021)

Clinical, laboratory data and inflammatory biomarkers at baseline as early discharge predictors in hospitalized SARS-CoV-2 infected patients
por: Trujillo-Rodriguez, María, et al.
Publicado: (2022)

Evaluation of neutralizing antibodies after vaccine BNT162b2: Preliminary data
por: Vietri, Maria Teresa, et al.
Publicado: (2022)

Decline of immune humoral response after BNT162b2 vaccine
por: Ferri, Sonia, et al.
Publicado: (2022)

Single -and Multi-Walled Carbon Nanotubes as Nanocarriers for the Delivery of 7-Hydroxyflavone
por: Espíndola, Cecilia, et al.
Publicado: (2022)

Acute myocarditis after administration of BNT162b2 vaccine against COVID-19
por: Cueva-Recalde, Juan F., et al.
Publicado: (2023)

Factors Associated with Adverse Reactions to BNT162b2 COVID-19 Vaccine in a Cohort of 3969 Hospital Workers
por: Rivera-Izquierdo, Mario, et al.
Publicado: (2021)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

Longitudinal dynamics of SARS-CoV-2-specific cellular and humoral immunity after natural infection or BNT162b2 vaccination
por: Almendro-Vázquez, Patricia, et al.
Publicado: (2021)

Boosting capacity of a fourth dose BNT162b2 in cancer patients
por: Debie, Yana, et al.
Publicado: (2023)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Analysis of Immunization, Adverse Events, and Efficacy of a Fourth Dose of BNT162b2 Vaccine in Health Workers in Mexico, a Pilot Study
por: Romero-Ibarguengoitia, Maria Elena, et al.
Publicado: (2022)

Evaluation of BNT162b2 Vaccine Effectiveness in Galicia, Northwest Spain
por: Pardo-Seco, Jacobo, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru
por: Vargas-Herrera, Natalia, et al.
Publicado: (2022)

Case report of Guillain-Barré Syndrome after COVID BNT162b2 mRNA vaccine()
por: Sosa-Hernández, Oscar, et al.
Publicado: (2022)

Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: Report of 5 cases
por: Rodríguez-Jiménez, Pedro, et al.
Publicado: (2021)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
por: Choi, Seong-Ho, et al.
Publicado: (2023)

Waning Immunity after the BNT162b2 Vaccine in Israel
por: Goldberg, Yair, et al.
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Mevorach, Dror, et al.
Publicado: (2022)

Acute interstitial nephritis after vaccination with BNT162b2
por: Rieckmann, Sonja, et al.
Publicado: (2022)

Effectiveness of BNT162b2 against COVID-19 in adolescents
por: Powell, Annabel A, et al.
Publicado: (2022)

Acute myocarditis following administration of BNT162b2 vaccine
por: Habib, Mhd Baraa, et al.
Publicado: (2021)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Witberg, Guy, et al.
Publicado: (2022)

Keratoplasty rejection after messenger RNA vaccine (BNT162b2) for COVID-19
por: Eduarda Andrade e Andrade, Maria, et al.
Publicado: (2022)

The value of the basophil activation test in the evaluation of patients reporting allergic reactions to the BNT162b2 mRNA COVID‐19 vaccine
por: Labella, Marina, et al.
Publicado: (2021)

Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers
por: Cocomazzi, Giovanna, et al.
Publicado: (2021)

Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection
por: Vietri, Maria Teresa, et al.
Publicado: (2022)

Évaluation de l'immunogénicité après vaccination COVID-19 hétérologue ChAdOx1-nCoV19/BNT162b2 et homologue BNT162b2/BNT162b2– Cohorte ANRS0001S COV-POPART
por: Lachâtre, M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mrc6qrl7uab3d6rl2vcv1nmj9o